Briefing
Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study
Baseline ctDNA above the median MMPM was associated with shorter PFS and OS in both arms (Pola-R-CHP PFS HR 1.96, OS HR 2.17; R-CHOP PFS HR 1.43, OS HR 2.10). A log-fold change of at least 2.0 or undetectable ctDNA at C2D1 was reached by 66.8% and 65.6% of patients in the two arms and was prognostic (PFS HR 1.86 and 2.21). In Pola-R-CHP, a 2.5-log reduction (PFS HR 2.89) and C2D1 clearance (PFS HR 2.98, OS HR 2.74) remained prognostic independent of baseline risk factors.
- n: paired baseline and Cycle 2 Day 1 results in 319/440 (Pola-R-CHP) and 299/439 (R-CHOP) patients
- Assay: AVENIO NHL CAPP-Seq; results as mean mutant molecules per mL